GHRH + GHRP combination · Compounded 503A · Subcutaneous
CJC-1295 + Ipamorelin: the cleanest synergistic GH-pulse stack.
CJC-1295 and ipamorelin are the most common GHRH-plus-GHRP pairing in clinical peptide medicine. CJC-1295 is a long-acting GHRH analogue; ipamorelin is a selective ghrelin-receptor agonist. Together they produce a larger, cleaner GH pulse than either peptide alone — without the cortisol and prolactin spillover seen with older GHRPs.
Free shipping over $150 · Pay with card or crypto
What CJC-1295 + Ipamorelin is
CJC-1295 is a 30-amino-acid synthetic analogue of GHRH 1-29 with stabilizing amino-acid substitutions for extended pituitary action. The "no-DAC" form lasts ~30 minutes — long enough to amplify a single pulse without continuous elevation.
Ipamorelin is a pentapeptide ghrelin-receptor agonist (GHRP) prized for its selectivity — it stimulates GH release without meaningfully raising cortisol, prolactin, or ACTH, which distinguishes it from older GHRPs like GHRP-2 and GHRP-6.
Used together (typically 100–300 mcg of each per dose), they exploit a known pharmacologic synergy: GHRH and GHRPs act on separate pituitary pathways, and co-stimulation produces a larger summed GH pulse than the additive sum of each alone.
How it works
CJC-1295 binds the GHRH receptor on pituitary somatotrophs, raising intracellular cAMP and priming GH synthesis and release.
Ipamorelin binds the ghrelin/growth-hormone-secretagogue (GHS) receptor, working through a phospholipase-C pathway and simultaneously suppressing somatostatin.
The two signals converge on the somatotroph to produce a synergistic GH pulse. Because ipamorelin is selective for the GHS receptor, there is minimal off-target rise in cortisol, prolactin, or aldosterone — the central reason this stack is preferred over older GHRP combinations.
What patients use it for
Larger physiologic GH pulse
Synergy between GHRH (CJC-1295) and GHRP (ipamorelin) outperforms either peptide alone — meaningful for patients seeking measurable IGF-1 response.
Clean side-effect profile
Ipamorelin's selectivity avoids the cortisol, prolactin, and hunger spikes associated with GHRP-2 and GHRP-6.
Sleep, recovery, and body composition
Typical benefits of GH-axis support: deeper sleep, faster connective-tissue recovery, modest visceral-fat reduction, modest lean-mass gain over 3–6 months.
Preserved feedback safety
Like sermorelin, this stack works upstream of the pituitary, so IGF-1 elevation stays inside physiologic range — not supraphysiologic the way exogenous HGH can be.
Evidence summary
Raun K et al. (Eur J Endocrinol, 1998) characterized ipamorelin as a selective GHRP with minimal cortisol or prolactin effect — the foundational paper.
Sackmann-Sala L et al. and pharmacologic reviews of GHRH + GHRP synergy show consistent larger GH AUC with combination dosing than monotherapy.
Direct long-term RCT evidence for the combined CJC-1295/ipamorelin stack in healthy adults is limited. The mechanistic case and clinical experience are strong; the formal trial literature for this specific pairing is not.
Dosing and clinical context
General clinical context only. Kindr Health physicians determine the appropriate dose and protocol for each patient based on history and labs. This is not a prescription or dosing recommendation.
Common protocol: 100–300 mcg of each peptide subcutaneously, 1–3 times daily, with one dose at bedtime to amplify the natural early-night GH pulse.
Avoid eating ~2 hours before injection. Elevated insulin and glucose blunt GH release.
Many clinicians use 3–6 month courses with periodic breaks. CJC-1295 no-DAC (short-acting) is preferred over CJC-1295 with DAC (long-acting) when the goal is preserving pulsatility rather than producing tonic elevation.
Safety and contraindications
Most common side effects: injection-site reaction, transient flushing, mild head pressure, vivid dreams (a GH-axis signature).
Contraindications: active malignancy, pregnancy, breastfeeding, proliferative diabetic retinopathy, severe insulin resistance.
CJC-1295 with DAC (long-acting) has been associated in case reports with sustained supraphysiologic IGF-1; for that reason most reputable U.S. clinics use the no-DAC formulation.
Compounded under physician supervision through a licensed 503A pharmacy. WADA prohibits this stack in competitive sport.
Who it's typically considered for
- Adults 35+ with symptoms suggestive of age-related GH decline (poor sleep, slow recovery, central adiposity)
- Patients who responded partially to sermorelin or ipamorelin monotherapy and want amplified pulse
- Patients prioritizing recovery and sleep over weight loss (a GLP-1 is more effective for weight)
- Patients prepared to monitor IGF-1 periodically and use the peptide in cycled courses
Frequently asked questions
Why combine CJC-1295 with ipamorelin?
GHRH and GHRPs activate pituitary somatotrophs through different intracellular pathways. Co-stimulation produces a synergistic GH pulse larger than the sum of each peptide alone — the central pharmacologic rationale for the combination.
CJC-1295 with DAC vs without DAC — which should I use?
No-DAC is preferred in most U.S. clinical use. It extends pituitary action long enough to amplify a single pulse, then clears. DAC formulations produce sustained GH elevation that can push IGF-1 supraphysiologic and is harder to titrate safely.
How long until I notice results?
Sleep changes often within 2–4 weeks. Body composition and recovery over 8–16 weeks. IGF-1 typically shifts measurably by 6–8 weeks of consistent dosing.
Is this the same as taking HGH?
No. HGH bypasses the pituitary and can drive IGF-1 supraphysiologic with no upstream brake. CJC-1295 + ipamorelin works through the pituitary, preserving physiologic negative feedback — a meaningfully safer profile for non-deficient adults.
Will this affect my appetite?
Ipamorelin's selectivity means it does not produce the strong hunger spike associated with GHRP-6. Most patients notice no meaningful appetite change.
Is it banned in sports?
Yes. WADA prohibits GHRH analogues and ghrelin-receptor agonists. Tested competitive athletes should not use it.
Can women use this stack?
Yes. Women in perimenopause and menopause frequently report meaningful sleep and recovery benefit. Avoid in pregnancy and breastfeeding.
How often do I need lab work?
Baseline IGF-1, then re-check at 8–12 weeks to confirm physiologic response and exclude supraphysiologic levels. Periodic monitoring is reasonable on longer courses.
Sources
- Raun K et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol (1998). — pubmed.ncbi.nlm.nih.gov/9849822
- Teichman SL et al. Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295. J Clin Endocrinol Metab (2006). — pubmed.ncbi.nlm.nih.gov/16352683
- Sigalos JT, Pastuszak AW. The Safety and Efficacy of Growth Hormone Secretagogues. Sex Med Rev (2018). — pubmed.ncbi.nlm.nih.gov/28526632
- Ionescu M, Frohman LA. Pulsatile secretion of growth hormone (GH) persists during continuous stimulation by CJC-1295. J Clin Endocrinol Metab (2006). — pubmed.ncbi.nlm.nih.gov/16968789
Considering CJC-1295 + Ipamorelin?
A Kindr Health physician reviews every longevity intake — peptides are prescribed only when medically indicated based on your history and labs. There is no charge for the initial review.
Related peptides
Medically reviewed by Kindr Health Clinical Team
Kindr Health Inc. — Editorial & Clinical Team (physician-supervised)
NPI 1609792902 · Last reviewed: July 3, 2026
Last reviewed July 3, 2026. Compounded medications are prepared by FDA-registered 503A pharmacies and are not FDA-approved drug products. Prescriptions require a clinical evaluation; a Kindr Health physician determines eligibility. Not for use in pregnancy. This page provides educational information and is not medical advice.